Skip to content

Steam inhalation and Nasal Irrigation For recurrent Sinusitis

A primary care randomised controlled trial of nasal irrigation and steam inhalation for recurrent sinusitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN88204146
Enrollment
316
Registered
2009-02-27
Start date
2008-12-01
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sinusitis Ear, Nose and Throat Chronic sinusitis

Interventions

Treatment and follow-ups will be for a 6-month period. Group 1. Daily nasal irrigation. Subjects will be asked to irrigate the nose (150 ml through each nostril) daily for 6 months. A neti pot will

Sponsors

University of Southampton (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients (both males and females) aged 18-65 years with recurrent or chronic sinusitis. Patients will be identified from GPs' computerised notes: those who have presented to their GP with 2+ episodes of acute or 1+ episode of chronic sinusitis in the last 3 years, who report moderate to severe impact of sinusitis symptoms on the quality of life.

Exclusion criteria

Exclusion criteria: 1. Inability to complete outcome measures 2. Head and neck cancer 3. HIV 4. Immunosuppressive treatment 5. Cystic fibrosis 6. Pregnancy/breastfeeding 7. Other nasal disorders e.g., polyps or other defect obstructing sinus 8. Poor gag or swallow reflexes

Design outcomes

Primary

MeasureTime frame
Severity of symptoms assessed by the Rhinosinusitis Disability Index (RSDI). During the feasibility stage RSDI and Sino-Nasal Outcome Test-20 (SNOT-20) will be recorded. Both are validated self-completion outcome measures for sinusitis. RSDI was used for the previous primary care study. It is anticipated that RSDI will be the primary outcome measure for this trial. However, if SNOT-20 is shown in the feasibility stage to be more sensitive to change it will be adopted as the primary outcome measure. Timepoints of assessment: 3 and 6 months.

Secondary

MeasureTime frame
From self-completion questionnaires at baseline, 3 and 6 months: 1. Quality of life assessed by the EQ-5D 2. Severity of sinus symptoms assessed by a Single-Item Sinus-Symptom Severity Assessment (SIA) 3. Severity of upper respiratory symptoms (coryza, sore throat, cough, earache, feeling unwell, fever) using format previously validated by our group 4. Belief in the importance of antibiotics and seeing the doctor for sinusitis using validated Likert scales From a daily diary for one week of the study period at 3 months: 5. Side effects of treatment (and also reported side effects for previous 3 months) 6. Compliance with irrigation/inhalation (to minimise reporting bias, patients will be given 'permission' not to perform the intervention) 7. Use of over the counter treatments (e.g., analgesics, decongestants) From notes review at the end of the follow-up period (at 6 months): 8. Number of prescriptions for antibiotics for sinus-related symptoms 9. Number of prescriptions for antibiotics in total 10. Number of GP visits regarding sinus-related symptoms and for other respiratory symptoms

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026